Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 8/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26857613 | 0.85 | ECE1 (0.43) | ECE1TDP1CASP1MME | |
| SCHEMBL25893776 | 0.83 | ECE1 (0.49) | ECE1CASP1ALDH1A1MEN1KMT2A | |
| SCHEMBL21734333 | 0.81 | ECE1 (0.56) | ECE1MEN1KMT2A | |
| SCHEMBL21566764 | 0.80 | ECE1 (0.46) | ECE1TDP1CASP1ALDH1A1LMNA | |
| SCHEMBL22952374 | 0.78 | ECE1 (0.44) | ECE1TDP1CASP1MMEALDH1A1 | |
| SCHEMBL14355660 | 0.77 | MME (0.38) | TDP1MMEALDH1A1GAAMEN1 | |
| SCHEMBL9911498 | 0.77 | MME (0.38) | TDP1MMEALDH1A1GAAMEN1 | |
| SCHEMBL19194706 | 0.77 | MME (0.38) | TDP1MMEALDH1A1GAAMEN1 | |
| SCHEMBL18933821 | 0.77 | ALDH1A1 (0.39) | ECE1MMEALDH1A1GAAMEN1 | |
| SCHEMBL24259709 | 0.77 | ECE1 (0.51) | ECE1TDP1CASP1MMEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11827906-B2 | Adeno-associated virus (AAV) clade f vector and uses therefor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230287451-A1 | NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-09-14 | — | — | US | disclosed |
| WO-2022262789-A1 | ANTITUMOR COMPOUND AND USE THEREOF | 明慧医药（杭州）有限公司 | 2022-12-22 | — | — | WO | disclosed |
| US-20220204990-A1 | NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-06-30 | — | — | US | disclosed |
| US-20220168330-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-3086814-B1 | DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | Bayer Pharma AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-10668167-B2 | Glucocorticoid receptor agonist and immunoconjugates thereof | ABBVIE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200056159-A1 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-02-20 | — | — | US | disclosed |
| US-20190262465-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-10323127-B2 | Poly(aspartic acid) derived co-polymers for a controlled release of perfuming ingredients | FIRMENICH SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180016396-A1 | POLY(ASPARTIC ACID) DERIVED CO-POLYMERS FOR A CONTROLLED RELEASE OF PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2018-01-18 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | KIF23, KIF2C, KIF18A | ECE1 2180/4885TDP1 2967/4885CASP1 4368/4885 |
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | ECE1 2107/4885TDP1 3874/4885CASP1 2771/4885 |
| US-20220168330-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | ECE1 3474/4885TDP1 386/4885CASP1 1646/4885 |
| US-20200056159-A1 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR | VSIG8, ASNS, FARSB | ECE1 3685/4885TDP1 918/4885CASP1 2712/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | ECE1 2802/4885TDP1 3200/4885CASP1 3198/4885 |
| US-10668167-B2 | Glucocorticoid receptor agonist and immunoconjugates thereof | NR3C1, NR3C2, MC2R | ECE1 2107/4885TDP1 3874/4885CASP1 2771/4885 |
| US-20220204990-A1 | NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING SAME | ELAVL1, ELAVL3, ANKRD54 | ECE1 4319/4885TDP1 1446/4885CASP1 3032/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ECE1 1476/4885TDP1 1273/4885CASP1 2784/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | ECE1 2029/4885TDP1 870/4885CASP1 505/4885 |
| US-11827906-B2 | Adeno-associated virus (AAV) clade f vector and uses therefor | ASNS, VSIG8, FARSB | ECE1 3602/4885TDP1 1048/4885CASP1 2898/4885 |
| US-20190262465-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | ECE1 2107/4885TDP1 3874/4885CASP1 2771/4885 |
| US-10323127-B2 | Poly(aspartic acid) derived co-polymers for a controlled release of perfuming ingredients | PHGDH, PARG, ACLY | ECE1 508/4885TDP1 2840/4885CASP1 570/4885 |
| US-20230287451-A1 | NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING SAME | ELAVL1, VSIG8, ELAVL3 | ECE1 4060/4885TDP1 1293/4885CASP1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.